The Huntington’s disease treatment market size has grown rapidly in recent years. It will grow from $0.73 billion in 2024 to $0.83 billion in 2025 at a compound annual growth rate (CAGR) of 13.3%. The growth observed in the historical period can be attributed to several factors, including increased awareness of genetic disorders, improved accessibility to genetic testing, higher investment in neurodegenerative disease research, a rise in the number of clinical trials for experimental therapies, and a growing pipeline of disease-modifying drugs.
The Huntington’s disease treatment market size is expected to see rapid growth in the next few years. It will grow to $1.35 billion in 2029 at a compound annual growth rate (CAGR) of 13%. The growth in the forecast period is expected to be driven by a stronger focus on personalized medicine, greater integration of digital health monitoring, increased regulatory support for orphan drugs, rising demand for therapies that provide symptomatic relief, and a higher demand for disease-modifying treatments. Key trends during this period are likely to include advancements in technology-driven gene silencing tools, the development of cell-based therapies, the emergence of peripheral biomarkers, the integration of telehealth into Huntington’s disease care, the incorporation of patient-reported outcomes, and continued innovation in disease-modifying drugs.
The growth of the Huntington’s disease treatment market is expected to be driven by the increasing use of gene therapies, which target genetic causes and slow disease progression. Gene therapies are treatments that alter or replace defective genes to cure or prevent diseases at the genetic level. As precision medicine continues to advance, gene therapies offer the ability to directly target the underlying genetic causes, leading to improved outcomes compared to traditional treatments. In Huntington’s disease, gene therapies aim to silence the defective HTT gene that produces harmful proteins, thus preventing nerve cell damage. This approach helps slow disease progression, protect brain function, and provides potential for long-term control. For example, in July 2023, the American Society of Gene & Cell Therapy (ASGCT) and Citeline reported that the number of gene therapies in phase II clinical trials increased by 5% from 247 to 260 by the end of Q2 2023. As such, the increase in gene therapies is contributing to the market’s growth.
Companies in the Huntington’s disease treatment market are also focusing on the development of advanced therapies, such as selective vesicular monoamine transporter 2 (VMAT2) inhibitor capsules, which aim to improve patient quality of life while slowing disease progression. VMAT2 inhibitors work by blocking a protein involved in packaging neurotransmitters for release in the brain. These drugs reduce neurotransmitter release, helping manage involuntary movements and other related symptoms. For example, in August 2023, Neurocrine Biosciences received FDA approval for Ingrezza (valbenazine) capsules, a once-daily oral VMAT2 inhibitor for the treatment of chorea associated with Huntington's disease in adults. This medication helps control involuntary movements by reducing excessive dopamine signaling in the brain and is available in various strengths, offering a convenient dosing option for patients.
In December 2024, PTC Therapeutics, a US-based pharmaceutical company developing treatments for Huntington’s disease, entered into a partnership with Novartis AG to advance the development of PTC518, a potential first-in-class oral, disease-modifying therapy for Huntington’s disease. This collaboration aims to accelerate the development and global commercialization of PTC518. Novartis AG, a Switzerland-based pharmaceutical company, specializes in drugs for Huntington’s disease.
Major players in the huntington’s disease treatment market are F. Hoffmann-La Roche Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, Bausch Health Companies Inc., Sun Pharmaceutical Industries Inc., H. Lundbeck A/S, WaVe Life Sciences Ltd., Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals plc, Lupin Limited, Neurocrine Biosciences Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Annexon Inc., Uniqure NV, Sage Therapeutics Inc., Azevan Pharmaceuticals Inc., Prilenia Therapeutics B.V.
North America was the largest region in the Huntington’s disease treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in Huntington's disease treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the Huntington's disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Huntington’s disease treatment consists of medical therapies aimed at managing the symptoms of this progressive neurological condition. The main objective is to slow the disease’s progression, reduce symptoms, and improve the patient’s quality of life.
The primary types of treatment for Huntington’s disease are symptomatic treatments and disease-modifying therapies. Symptomatic treatments focus on alleviating the symptoms of Huntington’s disease and enhancing quality of life, without targeting the underlying cause. These treatments are becoming increasingly sought after as patients look for better ways to manage daily challenges. Various methods are used to administer these treatments, including oral, intravenous, subcutaneous, and topical routes, for applications in genetic, neurological, and psychiatric disorders. These treatments are available through multiple distribution channels, such as hospital pharmacies, retail pharmacies, and online pharmacies, and are used by a wide range of end users, including hospitals, clinics, home care settings, and research institutions.
The Huntington’s disease treatment market research report is one of a series of new reports that provides Huntington’s disease treatment market statistics, including the Huntington’s disease treatment industry's global market size, regional shares, competitors with the Huntington’s disease treatment market share, detailed Huntington’s disease treatment market segments, market trends and opportunities, and any further data you may need to thrive in the Huntington’s disease treatment market. This Huntington’s disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The Huntington's disease treatment market consists of sales of products including tetrabenazine, deutetrabenazine, huntingtin-lowering therapies, cannabinoids, and cognitive enhancers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The Huntington’s disease treatment market size is expected to see rapid growth in the next few years. It will grow to $1.35 billion in 2029 at a compound annual growth rate (CAGR) of 13%. The growth in the forecast period is expected to be driven by a stronger focus on personalized medicine, greater integration of digital health monitoring, increased regulatory support for orphan drugs, rising demand for therapies that provide symptomatic relief, and a higher demand for disease-modifying treatments. Key trends during this period are likely to include advancements in technology-driven gene silencing tools, the development of cell-based therapies, the emergence of peripheral biomarkers, the integration of telehealth into Huntington’s disease care, the incorporation of patient-reported outcomes, and continued innovation in disease-modifying drugs.
The growth of the Huntington’s disease treatment market is expected to be driven by the increasing use of gene therapies, which target genetic causes and slow disease progression. Gene therapies are treatments that alter or replace defective genes to cure or prevent diseases at the genetic level. As precision medicine continues to advance, gene therapies offer the ability to directly target the underlying genetic causes, leading to improved outcomes compared to traditional treatments. In Huntington’s disease, gene therapies aim to silence the defective HTT gene that produces harmful proteins, thus preventing nerve cell damage. This approach helps slow disease progression, protect brain function, and provides potential for long-term control. For example, in July 2023, the American Society of Gene & Cell Therapy (ASGCT) and Citeline reported that the number of gene therapies in phase II clinical trials increased by 5% from 247 to 260 by the end of Q2 2023. As such, the increase in gene therapies is contributing to the market’s growth.
Companies in the Huntington’s disease treatment market are also focusing on the development of advanced therapies, such as selective vesicular monoamine transporter 2 (VMAT2) inhibitor capsules, which aim to improve patient quality of life while slowing disease progression. VMAT2 inhibitors work by blocking a protein involved in packaging neurotransmitters for release in the brain. These drugs reduce neurotransmitter release, helping manage involuntary movements and other related symptoms. For example, in August 2023, Neurocrine Biosciences received FDA approval for Ingrezza (valbenazine) capsules, a once-daily oral VMAT2 inhibitor for the treatment of chorea associated with Huntington's disease in adults. This medication helps control involuntary movements by reducing excessive dopamine signaling in the brain and is available in various strengths, offering a convenient dosing option for patients.
In December 2024, PTC Therapeutics, a US-based pharmaceutical company developing treatments for Huntington’s disease, entered into a partnership with Novartis AG to advance the development of PTC518, a potential first-in-class oral, disease-modifying therapy for Huntington’s disease. This collaboration aims to accelerate the development and global commercialization of PTC518. Novartis AG, a Switzerland-based pharmaceutical company, specializes in drugs for Huntington’s disease.
Major players in the huntington’s disease treatment market are F. Hoffmann-La Roche Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, Bausch Health Companies Inc., Sun Pharmaceutical Industries Inc., H. Lundbeck A/S, WaVe Life Sciences Ltd., Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals plc, Lupin Limited, Neurocrine Biosciences Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Annexon Inc., Uniqure NV, Sage Therapeutics Inc., Azevan Pharmaceuticals Inc., Prilenia Therapeutics B.V.
North America was the largest region in the Huntington’s disease treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in Huntington's disease treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the Huntington's disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Huntington’s disease treatment consists of medical therapies aimed at managing the symptoms of this progressive neurological condition. The main objective is to slow the disease’s progression, reduce symptoms, and improve the patient’s quality of life.
The primary types of treatment for Huntington’s disease are symptomatic treatments and disease-modifying therapies. Symptomatic treatments focus on alleviating the symptoms of Huntington’s disease and enhancing quality of life, without targeting the underlying cause. These treatments are becoming increasingly sought after as patients look for better ways to manage daily challenges. Various methods are used to administer these treatments, including oral, intravenous, subcutaneous, and topical routes, for applications in genetic, neurological, and psychiatric disorders. These treatments are available through multiple distribution channels, such as hospital pharmacies, retail pharmacies, and online pharmacies, and are used by a wide range of end users, including hospitals, clinics, home care settings, and research institutions.
The Huntington’s disease treatment market research report is one of a series of new reports that provides Huntington’s disease treatment market statistics, including the Huntington’s disease treatment industry's global market size, regional shares, competitors with the Huntington’s disease treatment market share, detailed Huntington’s disease treatment market segments, market trends and opportunities, and any further data you may need to thrive in the Huntington’s disease treatment market. This Huntington’s disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The Huntington's disease treatment market consists of sales of products including tetrabenazine, deutetrabenazine, huntingtin-lowering therapies, cannabinoids, and cognitive enhancers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Huntington’s Disease Treatment Market Characteristics3. Huntington’s Disease Treatment Market Trends And Strategies4. Huntington’s Disease Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market32. Global Huntington’s Disease Treatment Market Competitive Benchmarking And Dashboard33. Key Mergers And Acquisitions In The Huntington’s Disease Treatment Market34. Recent Developments In The Huntington’s Disease Treatment Market
5. Global Huntington’s Disease Treatment Growth Analysis And Strategic Analysis Framework
6. Huntington’s Disease Treatment Market Segmentation
7. Huntington’s Disease Treatment Market Regional And Country Analysis
8. Asia-Pacific Huntington’s Disease Treatment Market
9. China Huntington’s Disease Treatment Market
10. India Huntington’s Disease Treatment Market
11. Japan Huntington’s Disease Treatment Market
12. Australia Huntington’s Disease Treatment Market
13. Indonesia Huntington’s Disease Treatment Market
14. South Korea Huntington’s Disease Treatment Market
15. Western Europe Huntington’s Disease Treatment Market
16. UK Huntington’s Disease Treatment Market
17. Germany Huntington’s Disease Treatment Market
18. France Huntington’s Disease Treatment Market
19. Italy Huntington’s Disease Treatment Market
20. Spain Huntington’s Disease Treatment Market
21. Eastern Europe Huntington’s Disease Treatment Market
22. Russia Huntington’s Disease Treatment Market
23. North America Huntington’s Disease Treatment Market
24. USA Huntington’s Disease Treatment Market
25. Canada Huntington’s Disease Treatment Market
26. South America Huntington’s Disease Treatment Market
27. Brazil Huntington’s Disease Treatment Market
28. Middle East Huntington’s Disease Treatment Market
29. Africa Huntington’s Disease Treatment Market
30. Huntington’s Disease Treatment Market Competitive Landscape And Company Profiles
31. Huntington’s Disease Treatment Market Other Major And Innovative Companies
35. Huntington’s Disease Treatment Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Huntington’s Disease Treatment Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on huntington’s disease treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for huntington’s disease treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The huntington’s disease treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Treatment: Symptomatic Treatment; Disease-Modifying Therapies2) By Administration Type: Oral; Intravenous; Subcutaneous; Topical
3) By Therapeutic: Genetic Disorders; Neurological Disorders; Psychiatric Disorders
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
5) By End-User: Hospitals; Clinics; Homecare Settings; Research Centers
Subsegments
1) By Symptomatic Treatment: Antidepressants; Antipsychotics; Mood Stabilizers; Chorea Medications; Cognitive Enhancers2) By Disease-Modifying Therapies: Gene Therapy; Neuroprotective Agents; RNA-Based Therapies; Stem Cell Therapy; Protein-Targeting Therapies
Key Companies Profiled: F. Hoffmann-La Roche Ltd.; Novartis AG; Teva Pharmaceutical Industries Ltd.; Vertex Pharmaceuticals Incorporated; Bausch Health Companies Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Vertex Pharmaceuticals Incorporated
- Bausch Health Companies Inc.
- Sun Pharmaceutical Industries Inc.
- H. Lundbeck A/S
- WaVe Life Sciences Ltd.
- Dr. Reddy’s Laboratories Ltd.
- Hikma Pharmaceuticals plc
- Lupin Limited
- Neurocrine Biosciences Inc.
- Alnylam Pharmaceuticals Inc.
- PTC Therapeutics Inc.
- Ionis Pharmaceuticals Inc.
- Annexon Inc.
- Uniqure NV
- Sage Therapeutics Inc.
- Azevan Pharmaceuticals Inc.
- Prilenia Therapeutics B.V.